Immune Checkpoints and CAR-T Cells: The Pioneers in Future Cancer Therapies?

Immune Checkpoints and CAR-T Cells: The Pioneers in Future Cancer Therapies?


چاپ صفحه
پژوهان
صفحه نخست سامانه
چکیده مقاله
چکیده مقاله
نویسندگان
نویسندگان
دانلود مقاله
دانلود مقاله
دانشگاه علوم پزشکی تبریز
دانشگاه علوم پزشکی تبریز

نویسندگان: نگار حسین خانی , افشین درخشانی , مهدی عبدلی شادباد , خلیل حاجی اصغرزاده , امیر باغبانزاده , امیر علی مختارزاده , بهزاد برادران

کلمات کلیدی: cancer therapy; immune checkpoints; immunotherapy; CAR-T cells

نشریه: 15256 , 21 , 21 , 2020

اطلاعات کلی مقاله
hide/show

نویسنده ثبت کننده مقاله بهزاد برادران
مرحله جاری مقاله تایید نهایی
دانشکده/مرکز مربوطه مرکز تحقیقات ایمونولوژی
کد مقاله 74505
عنوان فارسی مقاله Immune Checkpoints and CAR-T Cells: The Pioneers in Future Cancer Therapies?
عنوان لاتین مقاله Immune Checkpoints and CAR-T Cells: The Pioneers in Future Cancer Therapies?
ناشر 12
آیا مقاله از طرح تحقیقاتی و یا منتورشیپ استخراج شده است؟ خیر
عنوان نشریه (خارج از لیست فوق)
نوع مقاله Review Article
نحوه ایندکس شدن مقاله ایندکس شده سطح یک – ISI - Web of Science
آدرس لینک مقاله/ همایش در شبکه اینترنت

خلاصه مقاله
hide/show

Although the ever-increasing number of cancer patients pose substantial challenges worldwide, finding a treatment with the highest response rate and the lowest number of side effects is still undergoing research. Compared to chemotherapy, the relatively low side effects of cancer immunotherapy have provided ample opportunity for immunotherapy to become a promising approach for patients with malignancy. However, the clinical translation of immune-based therapies requires robust anti-tumoral immune responses. Immune checkpoints have substantial roles in the induction of an immunosuppressive tumor microenvironment and tolerance against tumor antigens. Identifying and targeting these inhibitory axes, which can be established between tumor cells and tumor-infiltrating lymphocytes, can facilitate the development of anti-tumoral immune responses. Bispecific T-cell engagers, which can attract lymphocytes to the tumor microenvironment, have also paved the road for immunological-based tumor elimination. The development of CAR-T cells and their gene editing have brought ample opportunity to recognize tumor antigens, independent from immune checkpoints and the major histocompatibility complex (MHC). Indeed, there have been remarkable advances in developing various CAR-T cells to target tumoral cells. Knockout of immune checkpoints via gene editing in CAR-T cells might be designated for a breakthrough for patients with malignancy. In the midst of this fast progress in cancer immunotherapies, there is a need to provide up-to-date information regarding immune checkpoints, bispecific T-cell engagers, and CAR-T cells. Therefore, this review aims to provide recent findings of immune checkpoints, bispecific T-cell engagers, and CAR-T cells in cancer immunotherapy and discuss the pertained clinical trials.

نویسندگان
hide/show

نویسنده نفر چندم مقاله
نگار حسین خانیاول
افشین درخشانیدوم
مهدی عبدلی شادبادچهارم
خلیل حاجی اصغرزادهپنجم
امیر باغبانزادهششم
امیر علی مختارزادههشتم
بهزاد برادراندوازدهم

لینک دانلود مقاله
hide/show

نام فایل تاریخ درج فایل اندازه فایل دانلود
454-Immune Checkpoints and CAR-T Cells The Pioneers.pdf1399/09/085168959دانلود